Trending Now - Revolution Medicines Reports Promising Results for Pancreatic Cancer Treatment

WHO:

STAT - Revolution Medicines is the company involved in the development of the drug daraxonrasib.

CNBC - Mark Goldsmith is the CEO of Revolution Medicines.

CNBC - Benjamin Weinberg is an associate professor of medicine at Georgetown University.

WHAT:

STAT - The drug daraxonrasib resulted in a median survival of 13.2 months for patients, compared to 6.7 months for those receiving chemotherapy.

CNBC - The Phase 3 trial of daraxonrasib met all primary and secondary endpoints.

CNBC - The drug reduced the risk of death by 60% compared to chemotherapy.

CNBC - The company plans to seek FDA approval using a Commissioner's National Priority Voucher.

WHERE:

CNBC - The trial involved patients whose cancer had progressed on another treatment, although specific locations of the trial were not mentioned.

WHEN:

CNBC - The results were announced on Monday, April 11th, 2026.

CNBC - The company plans to seek FDA approval soon, although no specific date was provided.

WHY:

CNBC - The motivation behind the development of daraxonrasib is to provide a new treatment option for patients with pancreatic cancer, which has the lowest five-year survival rate of any major cancer at 13%.

HOW:

CNBC - Daraxonrasib targets RAS mutations, which are found in about 90% of pancreatic cancer cases.

CNBC - The drug is administered as a daily pill.

(UPDATED April 13, 2026 21:16 UTC)

Revolution Medicines has announced promising results for their drug daraxonrasib, which showed a median survival of 13.2 months for patients, significantly better than the 6.7 months for those receiving chemotherapy. The Phase 3 trial met all primary and secondary endpoints, reducing the risk of death by 60%, and the company plans to seek FDA approval soon using a Commissioner's National Priority Voucher. Daraxonrasib targets RAS mutations, present in about 90% of pancreatic cancer cases, and is administered as a daily pill, aiming to provide a new treatment option for this challenging disease.